• 1. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 2. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 3. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Application of (2R)-Piperazine-2-carboxylic Acid (CAS: 31321-68-3) in Chemical Biology and Pharmaceutical Research

The compound (2R)-piperazine-2-carboxylic acid (CAS: 31321-68-3) has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. As a chiral building block, this compound plays a crucial role in the synthesis of various biologically active molecules, including peptidomimetics, enzyme inhibitors, and drug candidates. Recent studies have highlighted its potential in addressing challenges related to drug delivery, target specificity, and metabolic stability.

One of the most notable advancements involves the use of (2R)-piperazine-2-carboxylic acid in the design of novel protease inhibitors. Researchers have demonstrated that incorporating this chiral scaffold into inhibitor structures enhances binding affinity and selectivity for target enzymes, such as HIV-1 protease and SARS-CoV-2 main protease. These findings, published in leading journals like Journal of Medicinal Chemistry and Bioorganic & Medicinal Chemistry Letters, underscore the compound's utility in antiviral drug development.

In addition to its role in drug design, (2R)-piperazine-2-carboxylic acid has shown promise in the field of peptide-based therapeutics. A 2023 study in Nature Chemical Biology reported its successful incorporation into cyclic peptides, resulting in improved membrane permeability and oral bioavailability. This breakthrough addresses a longstanding challenge in peptide drug development and opens new avenues for the treatment of chronic diseases.

Recent synthetic methodology developments have also expanded the accessibility of (2R)-piperazine-2-carboxylic acid derivatives. A team at MIT published an asymmetric synthesis protocol in Chemical Science (2023) that achieves high enantiomeric purity (>99% ee) with excellent yield, facilitating its broader application in medicinal chemistry. This advancement is particularly significant for scaling up production while maintaining the stereochemical integrity required for biological activity.

The compound's potential in central nervous system (CNS) drug discovery has emerged as another exciting research direction. Several pharmaceutical companies have included (2R)-piperazine-2-carboxylic acid derivatives in their CNS pipeline, with preclinical data showing improved blood-brain barrier penetration compared to traditional scaffolds. These developments were highlighted in recent presentations at the American Chemical Society National Meeting (Spring 2023).

Looking forward, researchers anticipate that (2R)-piperazine-2-carboxylic acid will play an increasingly important role in the development of next-generation therapeutics, particularly in areas requiring precise stereochemical control and multifunctional molecular architectures. Ongoing clinical trials involving derivatives of this compound are expected to yield important data within the next 2-3 years, potentially validating its therapeutic applications in oncology, infectious diseases, and neurological disorders.

• 126330-90-3((2R)-piperazine-2-carboxylic acid dihydrochloride)
• 89601-11-6(2,6-Piperazinedicarboxylicacid)
• 89601-10-5(2,5-Piperazinedicarboxylicacid)
• 158663-69-5((S)-Piperazine-2-carboxylic acid dihydrochloride)
• 2762-32-5(Piperazine-2-carboxylic acid)
• 100828-24-8(1-Piperazineaceticacid, 3-carboxy-)
• 721876-16-0(4-Methylpiperazine-2-carboxylic acid)
• 147650-70-2((2S)-piperazine-2-carboxylic acid)
• 3022-15-9(1-(piperazin-2-yl)ethen-1-ol dihydrochloride)
• 133525-05-0(Piperazine-2-carboxylic acid dihydrochloride)